Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results

AORT 10.24.2024

Full Press ReleaseSEC FilingsOur AORT Tweets

About Gravity Analytica

Recent News

  • 12.09.2024 - Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis
  • 11.19.2024 - Stifel 2024 Healthcare Conference
  • 11.07.2024 - Q3 2024 Artivion, Inc. Earnings Conference Call

Recent Filings

  • 12.23.2024 - 8-K Current report
  • 12.13.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.12.2024 - 144 Report of proposed sale of securities

ATLANTA,Oct. 24, 2024/PRNewswire/ --Artivion, Inc.(NYSE: AORT),a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial results will be released onThursday, November 7, 2024after the market closes. On that day, the Company will hold a teleconference call and live webcast at4:30 p.m. ETto discuss the results, followed by a question and answer session hosted byPat Mackin, Chairman, President and Chief Executive Officer ofArtivion.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13748263.

The live webcast and replay can be accessed on the Investors section of theArtivionwebsite atwww.artivion.comand by selecting Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investors section of theArtivionwebsite.

AboutArtivion, Inc.Headquartered in suburbanAtlanta, Georgia,Artivion, Inc.is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases.Artivion'sfour major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues.Artivionmarkets and sells products in more than 100 countries worldwide. For additional information aboutArtivion, visit our website,www.artivion.com.

Contacts:

Artivion

Lance A. Berry

Executive Vice President &

Chief Financial Officer

Phone: 770-419-3355

Gilmartin Group LLC

Brian Johnston/Laine Morgan

Phone: 332-895-3222

investors@artivion.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-release-date-and-teleconference-call-details-for-third-quarter-2024-financial-results-302286565.html

SOURCEArtivion, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com